# Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules

> **NCT01073553** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 26 (actual)

## Conditions studied

- Anti-Infective Agents

## Interventions

- **DRUG:** Cephalexin capsules (Optocef, BAYO5448 )
- **DRUG:** Cephalexin capsules (Keflex)

## Key facts

- **NCT ID:** NCT01073553
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2015-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01073553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01073553, "Cross-over Study to Prove Bioequivalence Between Two Brands of Cefalexin Capsules". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01073553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*